Abbreviated interim report 1 January – 31 March 2022

Significant successes for ICOres and ICOone

Iconovo and Galenica enters a strategic collaboration for the development of new inhalation products

Iconovo AB (publ), that develops complete inhalation products for a global market, has entered into a strategic collaboration with Galenica AB – a company specializing in the development and manufacture of pharmaceuticals for clinical studies. The main purpose of the collaboration is to facilitate the manufacturing of clinical trial material for companies developing new drugs for Iconovo's innovative single dose inhaler ICOone.

Iconovo extends collaboration with ISR with an agreement worth 13.6 million Swedish kronor (SEK)

Iconovo AB expands its collaboration with immunotherapy company Immune System Regulation (ISR) that accelerates the development of an inhaled vaccine for covid-19. The contract value of the collaboration between ISR and Iconovo increases by 13.6 million SEK. Iconovo is also entitled to low, single-digit royalty on the sale of the finalized product.

Abbreviated year-end report 1 January – 31 December 2021

Significant progress in Iconovo’s three strategic business areas

Iconovo announces completion of comparative clinical study of ICOres budesonide/formoterol and Symbicort Turbuhaler

Iconovo AB (publ), a company developing complete inhalation products for a global market, today announces that a clinical pilot pharmacokinetic study, comparing the pharmacokinetic profile of ICOres budesonide/formoterol and Symbicort® Turbuhaler®, has been successfully concluded. The study, which was carried out by Amneal Pharmaceuticals, has provided valuable data that supports continued development of ICOres budesonide/formoterol as a potential generic substitution of Symbicort® Turbuhaler® for the management of asthma and COPD.

Iconovo establishes Iconovo Pharma AB as a subsidiary for pharmaceutical sales in the Nordic countries

Iconovo AB (publ), that develops complete inhalation products for a global market, has registered the subsidiary Iconovo Pharma AB with the Swedish Companies Registration Office. This is part of the previously communicated strategy to establish an infrastructure for in-house pharmaceutical sales in the Nordic market. Iconovo's goal is to reach sales revenues of SEK 200 million by 2026, of which approximately one third is estimated to come from Iconovo Pharma.

Iconovo and TOA sign agreement for development of a generic product

Iconovo AB (publ), that develops complete inhalation products for a global market, and TOA Pharmaceutical Co., Ltd, which develops generic products for the Japanese market announced today that they have signed a feasibility agreement to use an inhaler from Iconovo for a generic product development. The feasibility agreement has a value of EUR 202.000 to be paid over the coming 12 months.

Nomination Committee appointed at Iconovo

At the Annual General Meeting of 8 May 2020, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September each year.

First granted ICOone® patent in China

The Chinese Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device ICOone.

Abbreviated interim report 1 January – 30 September 2021

New nasal inhaler has great potential in treatment of COVID-19